Deciphera Pharmaceuticals recently presented compelling two-year efficacy and safety data from its Phase 3 MOTION study, focusing on ROMVIMZA™ (vimseltinib) for patients suffering from Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress in Berlin. The findings, unveiled during the event held from October 17 to 21, 2025, underscore the potential of vimseltinib as a significant treatment option for patients unable to undergo surgical intervention.
Study Overview and Methodology
The global Phase 3 MOTION trial (NCT05059262) was designed to assess the effectiveness and safety of vimseltinib for patients with TGCT, particularly in scenarios where surgery is either not viable or would lead to unacceptable morbidity. The study comprises two parts: the first part involved a 24-week treatment phase where participants received either vimseltinib or a placebo. Those assigned to the placebo were given the opportunity to switch to vimseltinib during the second phase, which allowed all participants to receive the active treatment.
Notably, during this long-term treatment phase, patients were administered vimseltinib at a dosage of 30 mg twice weekly. The study aimed to evaluate the objective response rate (ORR) and duration of response (DOR) using specific criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and Tumor Volume Score (TVS).
Efficacy and Safety Results
The results presented highlight the sustained efficacy of vimseltinib over the two-year period. A total of 118 patients received vimseltinib, with results showing that 51% remained on treatment at the data cutoff of February 22, 2025. The ORR based on RECIST v1.1 criteria was reported at 48% for those randomized to vimseltinib and 54% for those who crossed over from the placebo. Additionally, the TVS assessment revealed an ORR of 81% for the vimseltinib group, indicating significant antitumor activity.
The safety profile of vimseltinib was consistent with previous findings, with most treatment-emergent adverse events being mild to moderate (grade 1/2). No new severe adverse events were reported, reinforcing the stability of vimseltinib’s safety profile. This data provides further support for vimseltinib as a viable treatment alternative for patients facing significant functional limitations due to TGCT.
About ROMVIMZA™ and TGCT
ROMVIMZA™, an oral tyrosine kinase inhibitor, is tailored to selectively inhibit the colony-stimulating factor 1 receptor (CSF1R), which plays a crucial role in the pathology of TGCT. The condition itself results from a malfunction in the CSF1 gene, leading to an overproduction of CSF1 and the recruitment of inflammatory cells, often resulting in painful and debilitating symptoms.
Deciphera’s commitment to developing innovative therapies is evident from its ongoing work in oncology, as demonstrated by the promising results of vimseltinib. The company’s focus on patient care is complemented by its collaboration with Ono Pharmaceutical Co., Ltd., which strives to bring effective therapies to patients globally.
As the landscape of treatment options for TGCT continues to evolve, the results from the MOTION study mark a significant step forward, offering hope to patients who have limited therapeutic avenues available to them. For further updates on Deciphera and its innovative treatments, visit their official website or follow them on social media platforms.
Related
